Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

277
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
277
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

389
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
389
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

216
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
216
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

347
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
347
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

329
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
329
Genetic Lingo01:11

Genetic Lingo

113.2K
Overview
113.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Self-disgust and its associated factors among patients with malignant lymphoma: a latent profile analysis.

BMC psychology·2026
Same author

Effects of unfolding case-based simulation in obstetrics and gynecology internships on caring ability and caring behaviors: a quasi-experimental study.

Frontiers in medicine·2026
Same author

Fault Reconstruction for Continuous-Time Switched Affine Systems With Actuator Faults via an Integrated UIO Approach.

IEEE transactions on cybernetics·2026
Same author

PDGF receptor-β-targeted copper-zinc nanozyme interfered glycolysis and remodelled tumor microenvironment for enhanced cuproptosis of lung cancer.

Colloids and surfaces. B, Biointerfaces·2026
Same author

The association between financial toxicity and mortality in hematologic malignancies: a systematic review and meta-analysis.

The oncologist·2026
Same author

Comparative study of bio-based and synthetic phase change materials functionalized coaxial fibers for photothermal-controlled drug delivery.

Biomaterials advances·2026

Related Experiment Video

Updated: Dec 20, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.1K

Identifying modifier genes for hypertrophic cardiomyopathy.

Yuanjian Chen1, Fuyi Xu2, Undral Munkhsaikhan3

  • 1Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America.

Journal of Molecular and Cellular Cardiology
|May 30, 2020
PubMed
Summary

Modifier genes influencing hypertrophic cardiomyopathy (HCM) severity were identified using BXD mice. Xin actin-binding repeat containing 2 (Xirp2) and nitric oxide synthase 3 (Nos3) emerged as key candidates for myocardial hypertrophy.

Keywords:
Hypertrophic cardiomyopathyModifier genesMurine genetic reference populationMyocyte hypertrophy

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.1K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.2K

Related Experiment Videos

Last Updated: Dec 20, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.1K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.1K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.2K

Area of Science:

  • Genetics
  • Cardiovascular Biology
  • Animal Models

Background:

  • Hypertrophic cardiomyopathy (HCM) severity varies significantly, influenced by unknown modifier genes.
  • The BXD murine genetic reference population (GRP) offers a powerful tool to identify these modifiers.
  • DBA/2J (D2) mice naturally exhibit HCM genetic basis and phenotypes.

Purpose of the Study:

  • To identify novel modifier genes regulating myocardial hypertrophy in HCM.
  • To leverage the BXD GRP for genetic mapping of HCM-related traits.

Main Methods:

  • Cardiomyocyte size was measured in BXD strains and parental strains (C57BL/6J and DBA/2J).
  • Quantitative Trait Locus (QTL) mapping was performed using WebQTL on GeneNetwork.
  • Candidate genes were prioritized based on QTL scores and correlation with gene expression.

Main Results:

  • Significant QTLs for cardiomyocyte size were identified on chromosomes 2 and 5.
  • Xin actin-binding repeat containing 2 (Xirp2) on chromosome 2 received a high QTL score.
  • Nitric oxide synthase 3 (Nos3) on chromosome 5 showed the highest score and significant correlation with cardiomyocyte size.

Conclusions:

  • Xirp2 and Nos3 are identified as novel candidate modifier genes for HCM-related myocardial hypertrophy.
  • These findings provide a foundation for future validation studies of Xirp2 and Nos3 in HCM pathogenesis.